Clinical trials of KAF156 begin in 9 countries across Africa and Asia
by Clive Cookson
Science Editor, Financial Times, August 21, 2017
Read online at:
The first new malaria drug to emerge for 20 years is beginning clinical trials in nine countries across Africa and Asia. KAF156 could be “a game changer”, its developers say, at a time when the malaria parasite is evolving resistance to existing treatments. Novartis, the Swiss drug company, has developed KAF156 in collaboration with Medicines for Malaria Venture (MMV), a public-private partnership, and charities including the Wellcome Trust and Gates Foundation. Research suggests that the new medicine quickly clears malaria infection, including resistant strains, and blocks transmission of the parasite.